Generic Manufacturers Try To Up Their Game As US Pressure Persists

The challenging US pricing environment for generic drugs appears poised to continue through 2017, presenting a long-lasting headache for manufacturers, which rely on the enormous US market to drive growth. While one of the biggest headwinds – FDA's effort to reduce the backlog of abbreviated new drug applications (ANDAs) – is normalizing, others like customer consolidation and smaller patent expiration opportunities will continue to put pressure on the business segment.

Generic drug manufacturers are looking increasingly to high barrier-to-entry products like sterile injectables, complex generics and biosimilars to drive growth,...